From Pharmacogenomics to Pharmaco-Omics: An Integrated Multi-Omics Framework for Precision Medicine

Despite major advances in pharmacotherapy, patients receiving identical drugs at equivalent doses often experience markedly different therapeutic outcomes. Such variability ranges from optimal efficacy to severe toxicity or complete lack of response, underscoring the limitations of population-based prescribing models [1,2]. Adverse drug reactions (ADRs) remain a significant cause of morbidity, hospitalization, and healthcare expenditure worldwide [3].

Pharmacogenomics (PGx) addresses this challenge by elucidating how inherited genetic variation influences drug pharmacokinetics and pharmacodynamics. Early pharmacogenetic discoveries demonstrated that polymorphisms in drug-metabolizing enzymes could profoundly alter drug exposure, establishing the molecular basis for individualized therapy [4,5]. With the completion of the Human Genome Project and advances in sequencing technologies, pharmacogenomics has evolved into a genome-wide discipline integrated within precision medicine [1,6].

In recent years, the scope of pharmacogenomics has expanded further to include dynamic modifiers of drug response such as epigenetic regulation, microbiome composition, and metabolic state. These advances, coupled with improved analytical resolution and translational frameworks, have significantly strengthened the clinical relevance of pharmacogenomics in 2025. This review provides an integrated synthesis of molecular mechanisms, clinical applications, and emerging innovations shaping the future of pharmacogenomics-driven precision medicine.

2. Conceptual Foundations of Pharmacogenomics

Pharmacogenetics traditionally focused on discrete gene–drug interactions, often involving variants with large functional effects. Classic examples include polymorphisms in N-acetyltransferase, thiopurine S-methyltransferase (TPMT), and cytochrome P450 enzymes, which were shown to influence drug metabolism and toxicity [4,7]. While these discoveries validated the concept of genetically guided therapy, they captured only a fraction of the complexity underlying drug response.

Pharmacogenomics extends this paradigm by encompassing genome-wide variation and interactions among multiple genes, pathways, and biological systems [1,6]. Within precision medicine, pharmacogenomics serves as a bridge between molecular genetics and rational therapeutics, enabling drug selection and dose optimization based on individual genomic profiles rather than empirical trial-and-error prescribing [2,6].

3. Molecular Mechanisms Underlying Pharmacogenomic Variability

3.1 Genetic Determinants of Pharmacokinetics

Genetic variation affecting drug absorption, distribution, metabolism, and elimination represents the most extensively characterized domain of pharmacogenomics. Polymorphisms in cytochrome P450 enzymes—such as CYP2D6, CYP2C9, CYP2C19, and CYP3A5—can markedly alter systemic drug exposure, influencing both efficacy and toxicity [1,8]. Similarly, variation in conjugating enzymes, including UGTs and TPMT, affects drug clearance and risk of dose-dependent adverse effects [7,9].

Drug transporters, such as SLCO1B1 and ABC family proteins, further modulate pharmacokinetics by regulating drug uptake and efflux across biological membranes. Genetic variation in these transporters contributes to interindividual differences in bioavailability and tissue distribution [6,10].

3.2 Pharmacodynamic and Target-Level Variability

Beyond pharmacokinetics, genetic variation in drug targets—including receptors, enzymes, and ion channels can influence pharmacodynamic response. Such variants may alter receptor sensitivity, signaling efficiency, or downstream pathway activation, thereby modifying therapeutic outcomes [6,11]. Unlike pharmacokinetic variants, pharmacodynamic effects are often polygenic and context-dependent, complicating their translation into routine clinical practice.

3.3 Immunogenetic Mechanisms and Adverse Drug Reactions

Certain severe adverse drug reactions are mediated by immune mechanisms linked to specific human leukocyte antigen (HLA) alleles. These reactions are typically idiosyncratic, dose-independent, and potentially life-threatening. Pharmacogenomic screening for HLA variants has therefore emerged as a powerful preventive strategy in selected drug therapies [1,12].

Table 1: Molecular Determinants of Pharmacogenomic Variability and Their Clinical Relevance

4. Clinical Utility of Pharmacogenomic Biomarkers

4.1 Optimizing Drug Efficacy through Genotype-Guided Therapy

The primary clinical objective of pharmacogenomics is to improve therapeutic outcomes by aligning drug selection and dosing with an individual’s genetic profile. Variants affecting drug-metabolizing enzymes can lead to substantial differences in systemic drug exposure, making standard dosing inappropriate for a significant subset of patients [13,14]. Genotype-guided dosing strategies have demonstrated benefits across multiple therapeutic areas, including oncology, cardiology, psychiatry, and infectious diseases [6,15].

Clinical studies indicate that a majority of patients carry at least one pharmacogenomic variant associated with altered drug response, underscoring the broad relevance of pharmacogenomics to routine prescribing [16]. By identifying patients at risk of subtherapeutic exposure or excessive toxicity, pharmacogenomic testing supports rational dose optimization and reduces the need for empirical dose adjustments [14,15].

4.2 Prevention of Adverse Drug Reactions

Adverse drug reactions remain a major cause of preventable morbidity and healthcare utilization. Type A reactions, which are dose-dependent and predictable, are frequently linked to pharmacokinetic variability and can be mitigated through genotype-guided dosing [1,13]. In contrast, Type B reactions are often immune-mediated and unpredictable, yet pharmacogenomics has enabled risk stratification for several severe idiosyncratic reactions through identification of specific genetic markers, particularly HLA alleles [12,17].

Implementation studies suggest that pharmacogenomic-guided prescribing can significantly reduce the incidence of clinically relevant adverse drug reactions, leading to improved patient safety and potential cost savings [18,19]. These findings highlight the role of pharmacogenomics not only as a tool for therapeutic optimization but also as a preventive strategy within precision medicine.

4.3 Actionability, Guidelines, and Evidence Stratification

The clinical impact of pharmacogenomics depends on the strength of evidence supporting specific gene–drug associations and the availability of actionable prescribing recommendations. International consortia and regulatory bodies have developed frameworks to categorize pharmacogenomic information based on clinical validity and utility, distinguishing between informative biomarkers and those warranting therapeutic action [6,20].

Clinical practice guidelines increasingly incorporate pharmacogenomic data to guide prescribing decisions, though the degree of actionability varies across drug–gene pairs. This stratified approach is essential to ensure responsible integration of pharmacogenomics into clinical care and to avoid overinterpretation of preliminary genetic associations [20,21].

Table 2: Barriers and Emerging Solutions in the Clinical Implementation of Pharmacogenomics

5. Advances Strengthening Pharmacogenomics in 2025

5.1 High-Resolution Sequencing and Complex Pharmacogenes

One of the most transformative advances enhancing pharmacogenomics in 2025 is the increasing application of long-read sequencing technologies. Many pharmacogenes of high clinical relevance—such as CYP2D6, UGT1A1, and HLA loci—exhibit complex genomic architectures characterized by copy-number variation, hybrid gene formation, and repetitive haplotypes [22,23]. These features are often inadequately resolved by conventional genotyping arrays and short-read sequencing.

Long-read sequencing enables accurate characterization of structural variants and facilitates the discovery of novel alleles across multiple pharmacogenes, including CYP2D6, CYP2B6, CYP2C9, CYP2C19, CYP4F2, and SLCO1B1 [22–24]. Improved allelic resolution strengthens genotype–phenotype correlations and enhances pharmacogenomic interpretation, particularly in ethnically diverse populations that have historically been underrepresented in genomic research [23,25].

Emerging targeted sequencing approaches and adaptive sampling strategies are further reducing cost and turnaround time, suggesting that high-resolution pharmacogene analysis may become increasingly feasible in routine clinical settings [24,26]. These developments mark a shift from technology-limited pharmacogenomics toward more analytically robust precision therapeutics.

5.2 Standardization of Genotype-to-Phenotype Translation

As pharmacogenomic testing expands, inconsistent interpretation of genetic results has emerged as a major barrier to clinical scalability. Differences in allele function assignment, phenotype classification, and reporting practices can lead to variability in clinical recommendations, undermining confidence among healthcare providers [6,27].

Recent efforts emphasize standardized genotype-to-phenotype translation frameworks, particularly for cytochrome P450 enzymes and other highly polymorphic pharmacogenes. Harmonized systems for assigning functional status and translating diplotypes into metabolic phenotypes are essential for interoperability across laboratories, healthcare systems, and electronic health record platforms [20,27].

In 2025, such standardization is increasingly recognized as a prerequisite for effective clinical decision support and equitable implementation of pharmacogenomics across healthcare settings.

Table 3: Recent Advances and Future Directions in Pharmacogenomics-Driven Precision Medicine

6. Beyond Genomics: Expansion toward Pharmaco-Omics

6.1 Epigenetics and Regulation of Drug Response

While genetic variants provide a stable framework for pharmacogenomic prediction, gene expression and enzyme activity are subject to epigenetic regulation. DNA methylation, histone modifications, and non-coding RNAs can modulate the expression of pharmacogenes in response to disease states, inflammation, aging, and environmental exposures [28,29]. These mechanisms contribute to variability in drug response that cannot be explained by genotype alone.

Figure 1: Integration of multi-omic determinants in pharmacogenomics-driven precision therapy

6.2 Microbiome, Metabolomics, and Functional Readouts

The human microbiome has emerged as a significant modulator of drug metabolism, influencing drug activation, inactivation, and toxicity. Interindividual differences in microbial composition contribute to variability in drug response and may alter therapeutic outcomes independently of host genotype [30,31].

Metabolomics provides functional insights into real-time drug exposure and response, offering a complementary layer to genomic data. By capturing downstream biochemical effects, metabolomic profiling can help bridge the gap between genotype and observed phenotype [32,33].

6.3 Phenoconversion and Clinical Complexity

The integration of genetic and non-genetic factors has reinforced the concept of phenoconversion, wherein an individual’s observed drug response phenotype diverges from that predicted by genotype. Phenoconversion may result from drug–drug interactions, comorbid conditions, or environmental influences and is particularly relevant in patients with polypharmacy or chronic disease [2,34].

Recognition of phenoconversion underscores the need for adaptive, integrative models of precision medicine that extend beyond static genetic information.

7.1 Models of Pharmacogenomic Testing

Clinical implementation of pharmacogenomics requires careful consideration of testing strategies. Two principal models are commonly described: reactive testing, performed at the point of care in response to a specific prescribing decision, and pre-emptive testing, in which a panel of pharmacogenes is analyzed in advance and stored for future use [6,35]. While reactive testing minimizes upfront costs, pre-emptive approaches offer greater long-term efficiency by enabling immediate access to pharmacogenomic information during prescribing.

Panel-based testing is increasingly favored over single-gene assays due to declining sequencing costs and the recognition that multiple pharmacogenes influence drug response across therapeutic areas [20,27]. However, panel testing also introduces challenges related to variant interpretation, data storage, and clinical reporting, underscoring the importance of standardized translation frameworks and decision support tools [27,36].

7.2 Integration into Healthcare Systems

For pharmacogenomics to meaningfully influence prescribing behavior, test results must be seamlessly integrated into electronic health records (EHRs) and coupled with clinical decision support systems (CDSS). Such systems can deliver point-of-care guidance, translating complex genetic data into actionable prescribing recommendations [6,36].

Successful implementation programs emphasize multidisciplinary collaboration involving clinicians, pharmacists, genetic laboratories, information technology teams, and hospital leadership. Pharmacists, in particular, play a central role in interpreting pharmacogenomic results and guiding medication optimization, positioning them as key drivers of pharmacogenomics in clinical practice [6,37].

Figure 2: Workflow for integration of pharmacogenomics into clinical practice.